Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.

The Lancet. Oncology·2024
Same author

Adding a Gene Expression Profile Test to Aid Differential Diagnosis and Treatment in Aggressive Large B-Cell Lymphoma: An Early Exploratory Economic Evaluation.

Applied health economics and health policy·2023
Same author

An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease.

Nature medicine·2023
Same author

Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients.

American journal of cancer research·2023
Same author

Alternative tissue fixation for combined histopathological and molecular analysis in a clinically representative setting.

Histochemistry and cell biology·2021
Same author

Creation of a novel simple heat mapping method for curriculum mapping, using pathology teaching as the exemplar.

BMC medical education·2021

Related Experiment Video

Updated: Jun 26, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Pathologic evaluation of unknown primary cancer.

Karin A Oien1

  • 1Division of Cancer Sciences and Molecular Pathology, Faculty of Medicine, University of Glasgow, United Kingdom. k.oien@beatson.gla.ac.uk

Seminars in Oncology
|January 31, 2009
PubMed
Summary

Diagnosing unknown primary cancer (UPC) involves a stepwise approach using clinical context, morphology, and immunohistochemistry (IHC). This review details the diagnostic process, from initial biopsy to predicting primary tumor site for adenocarcinomas.

More Related Videos

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Related Experiment Videos

Last Updated: Jun 26, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Area of Science:

  • Pathology
  • Oncology
  • Cancer Diagnostics

Background:

  • Metastases of unknown primary cancer (UPC) present a diagnostic challenge.
  • Accurate diagnosis is crucial for effective patient treatment and management.

Purpose of the Study:

  • To provide a comprehensive review of the pathologic approach to diagnosing unknown primary cancer (UPC).
  • To guide pathologists and oncologists in identifying malignancy, broad tumor typing, and predicting primary tumor site for adenocarcinomas.

Main Methods:

  • Review of established diagnostic procedures for UPC.
  • Integration of clinical context, histomorphology, and immunohistochemistry (IHC).
  • Detailed discussion of IHC markers, staining patterns, and diagnostic dilemmas for various tumor types.

Main Results:

  • A stepwise diagnostic algorithm for UPC is presented.
  • Key morphologic features and IHC markers for differentiating major tumor categories (carcinoma, melanoma, lymphoma, sarcoma) are outlined.
  • Specific guidance is provided for subtyping carcinomas and predicting primary sites for adenocarcinomas.

Conclusions:

  • The described pathologic approach, utilizing morphology and IHC, is effective for diagnosing UPC.
  • Accurate tissue handling and IHC interpretation are essential for optimal diagnostic outcomes.
  • This review serves as a valuable resource for oncologists and pathologists managing UPC cases.